Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor
ABSTRACT Epaminurad, a novel uricosuric agent, exhibits potent inhibitory activity against the human uric acid transporter. This study aimed to investigate the effects of renal function and food intake on the pharmacokinetic, pharmacodynamic, and safety characteristics of 9 mg epaminurad. This study...
Saved in:
| Main Authors: | Seo Yeong Park, Jun Gi Hwang, Sung Kweon Cho, Min Kyu Park |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70266 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study
by: Jae-Bum Jun, et al.
Published: (2025-05-01) -
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01) -
Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients
by: Aurema Otero, et al.
Published: (2024-09-01) -
The dose of febuxostat required to achieve the target level of uric acid in patients with normal and impaired renal function
by: M. S. Eliseev, et al.
Published: (2025-04-01) -
Uric Acid, Colchicine and Chronic Inflammatory Diseases: A Cardiovascular Perspective
by: Alessia Alunno, et al.
Published: (2025-06-01)